USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
Product and Pipeline Analysis of the Global Therapeutic Lipid Modulators Market
Product and Pipeline Analysis of the Global Therapeutic Lipid Modulators Market
Relentless Pursuit of Blockbuster Cardiovascular Therapeutics
RELEASE DATE
20-Jun-2014
20-Jun-2014
REGION
North America
North America
Research Code: NDDD-01-00-00-00
SKU: LS00123-NA-MR_16964
$3,950.00
In stock
SKU
LS00123-NA-MR_16964
Description
Dyslipidemia exists in many forms and is prevalent in developed regions. Although many patients with moderately elevated lipids are well served by available therapies, there is a significant patient population for whom these therapies are inappropriate or inadequate, thereby prompting development of innovative therapies to fill the gaps. This research service includes comprehensive information on the market background, analyses of drug development, detailed product and pipeline analyses, detailed product profiles for key marketed/late-stage products, and a global overview. The research service also provides time-sensitive details such as new product launch timelines, PCSK9 Phase 3 programs, and patent expirations.
Table of Contents
Executive Summary
Executive Summary (continued)
Recent Market Developments
Defining Healthcare Trends in the Future
Companies to Watch
Methodology and Scope
Introduction
Lipid and Lipoprotein Basics
Prevalence of Elevated Cholesterol in Major Markets
Prevalence of Elevated Cholesterol in Major Markets (continued)
Prevalence and Management of Elevated LDL-C in the United States
Classification of Lipoprotein Levels
Classification of Familial Dyslipidemias
ACC/AHA Practice Guidelines
ACC/AHA Practice Guidelines (continued)
ACC/AHA Practice Guidelines (continued)
European Practice Guidelines
Market Segmentation
Market Segmentation (continued)
Market Segmentation (continued)
Competitive Landscape—Number of Marketed and Pipeline Products
Competitive Landscape—Marketed and Pipeline Products
Marketed Product Analysis
Marketed Product Analysis (continued)
Marketed Product Analysis (continued)
Marketed Product Analysis (continued)
Marketed Product Analysis (continued)
Marketed Product Analysis (continued)
Marketed Product Analysis (continued)
Pipeline Analysis
Pipeline Analysis—Products in Clinical Development (continued)
Pipeline Analysis—Products in Clinical Development (continued)
Pipeline Analysis—Products in Clinical Development (continued)
Pipeline Analysis—Products in Clinical Development (continued)
Pipeline Analysis—Products in Clinical Development (continued)
Pipeline Analysis—Products in Clinical Development (continued)
Product Launch Timeline
Patent Expiration Timeline
Phase 3 Clinical Program—Evolocumab (Amgen)
Phase 3 Data Readouts—Evolocumab (Amgen)
Phase 3 Clinical Program—Alirocumab (Sanofi/Regeneron)
Phase 3 Clinical Program—Bococizumab (Pfizer)
Comparative Efficacy Analysis
Comparative Efficacy Analysis Discussion
Product Dashboard—Kynamro (mipomersen sodium)
Product Dashboard—Juxtapid/Lojuxta (lomitapide)
Product Dashboard—Vascepa (icosapent ethyl)
Product Dashboard—Evolocumab (AMG145)
Product Dashboard—Alirocumab (REGN727)
Product Dashboard—Bococizumab (RN316)
Conclusions and Recommendations
Legal Disclaimer
The Frost & Sullivan Story
Value Proposition
Global Perspective
Industry Convergence
360º Research Perspective
Implementation Excellence
Our Blue Ocean Strategy
Popular Topics
Dyslipidemia exists in many forms and is prevalent in developed regions. Although many patients with moderately elevated lipids are well served by available therapies, there is a significant patient population for whom these therapies are inappropriate or inadequate, thereby prompting development of innovative therapies to fill the gaps. This research service includes comprehensive information on the market background, analyses of drug development, detailed product and pipeline analyses, detailed product profiles for key marketed/late-stage products, and a global overview. The research service also provides time-sensitive details such as new product launch timelines, PCSK9 Phase 3 programs, and patent expirations.
| No Index | No |
|---|---|
| Podcast | No |
| Author | Jennifer Lazar |
| WIP Number | NDDD-01-00-00-00 |
| Is Prebook | No |